Kazia Therapeutics Limited (KZIA)

NASDAQ: KZIA · USD

$8.27

+0.10 (+1.2%)· Recorded snapshot

Market cap	113.3M
Revenue (ttm)	1.3M
Net income (ttm)	-15.2M
EPS (ttm)	-$6.82
Shares out	13.7M
Volume	146,120
Beta	2.27

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.3M
Net income (ttm): -15.2M
EPS (ttm): -$6.82
Market cap: 113.3M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	نگه‌داری

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-106.9

P25 n/aP50 n/aP75 n/a

ROIC-53.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All KZIA indicators

Market & fundamental data

Available fields

200

Groups with data

Currency

AUD

Showing 200 of 200 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001075880
Company name	Kazia Therapeutics Limited
Country	Australia
Country code	US
CUSIP number	48669G303
Earnings date	2026-11-10
Earnings time	bmo
Employees	6
Employees change	-1
Employees growth	-11.76%
Enterprise value	$67.1M
Exchange	NASDAQ
Financial currency	AUD
Financial report date	2025-12-31
First seen	2026-05-09
Fiscal year end	June
Founded	1994
Industry	Biotechnology
IPO date	1999-01-06
Is primary listing	Yes
Is SPAC	No
ISIN number	US48669G3039
Last earnings date	2026-03-30
Last refreshed	2026-10-28
Last stock split date	2025-04-17
Last stock split type	Reverse
Market cap	$113.3M
Market cap category	Micro-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$8.27
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	KZIA
Website	https://www.kaziatherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-82.46%
EV/Sales	51.87x
FCF / EV yield	-15.41%
FCF yield	-9.04%
Forward EV/Sales	90.23x
Forward P/S	153.78x
P/B ratio	2.99x
P/S ratio	88.41x
Price / tangible book value	3.7x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-964.22%
Pretax margin	-1,285.72%
Profit per employee	$-2.5M
Revenue per employee	$211,072
ROA	-25.7%
ROA (5Y)	-45.34%
ROCE	-39.17%
ROE	-106.9%
ROIC	-53.34%
SBC / revenue	254.04%
Tax / revenue	-84.82%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	3
Gross profit growth	-24.15%
Gross profit growth (Q)	1,838,320%
Gross profit growth 5Y	39.18%
Net income growth years	1
Revenue growth	-24.15%
Revenue growth (Q)	312.39%
Revenue growth (QoQ)	-94.91%
Revenue growth 10Y	-4.98%
Revenue growth 5Y	39.18%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$327,927
EBIT	$-12.2M
EBITDA	$-11.9M
EPS	$-6.82
FCF per share	$-0.74
Financing cash flow	$54.4M
Free cash flow	$-10.1M
Free cash flow minus SBC	$-13.5M
Gross profit	$1.3M
Income taxes	$-1.1M
Net cash flow	$44.3M
Net income	$-15.2M
Operating cash flow minus SBC	$-13.5M
Operating income	$-12.2M
Revenue	$1.3M
Stock-based compensation	$3.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-2.53
Book value per share	$2.73
Debt / equity	0
Long-term assets	$-1.8M
Long-term liabilities	$-701,933
Net cash (debt)	$46.3M
Net cash / market cap	41.32%
Net cash growth	2,065.3%
Net debt / equity	-1.49
Piotroski F-Score	2
Shareholders' equity	$31M
Tangible book value	$30.3M
Tangible book value per share	$2.67
Total assets	$47.4M
Total cash	$46.3M
Total debt	$65,906
Total liabilities	$16.4M
WACC	16.73%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.04
Current assets	$49.2M
Current liabilities	$17.1M
Current ratio	2.87
Net working capital	$-15.8M
Quick ratio	2.86
Working capital	$30.4M
Working capital turnover	0.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-213.01%
Dividend yield	0%
Shareholder yield	-213.01%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-97.41%
10Y return CAGR	-30.6%
10Y total return	-97.41%
150-day SMA	$11.69
15Y price change	-98.66%
15Y return CAGR	-19.22%
15Y total return	-95.93%
1D price change	1.22%
1M price change	-13.27%
1M total return	-13.27%
1W price change	5.33%
1W total return	5.33%
1Y price change	13.7%
1Y return CAGR	13.71%
1Y total return	13.7%
20-day SMA	$8.34
200-day SMA	$10.53
20Y price change	-99.92%
20Y return CAGR	-26.02%
20Y total return	-99.76%
3M price change	-32.02%
3M total return	-32.02%
3Y price change	-70.88%
3Y return CAGR	-33.71%
3Y total return	-70.88%
50-day SMA	$10.44
50-day SMA vs 200-day SMA	50under200
52-week high	$17.40
52-week high date	2025-12-08
52-week low	$4.86
52-week low date	2026-02-12
5Y price change	-98.42%
5Y return CAGR	-56.39%
5Y total return	-98.42%
6M price change	-30.54%
6M total return	-30.54%
All-time high	$31,900.00
All-time high date	2003-12-08
All-time low	$2.86
All-time low date	2025-04-17
Average true range (ATR)	$0.70
Average volume	213.3K
Beta (1Y)	3.51
Beta (2Y)	1.83
Beta (5Y)	2.27
Change from 52-week high	-52.47%
Change from 52-week low	70.17%
Change from all-time high	-99.97%
Change from all-time low	190.21%
Change from open	1.1%
Day's gap	0.12%
Dollar volume	$1.2M
High price	$8.35
Low price	$8.10
Monthly RSI	38.52
Open price	$8.18
Position in 52-week range	68%
Previous close	$8.17
Price vs 150-day SMA	-29%
Price vs 20-day SMA	-0.49%
Price vs 200-day SMA	-21.14%
Price vs 50-day SMA	-20.51%
Relative volume	0.68
RSI	43.43
Sharpe ratio	0.67
Sharpe ratio (3Y)	0.45
Sharpe ratio (5Y)	0.06
Sortino ratio	1.17
Sortino ratio (3Y)	1.12
Sortino ratio (5Y)	0.17
Volume	146.1K
Weekly RSI	40.06
YTD price change	20.46%
YTD total return	20.46%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	11.4M
Float percentage	82.85%
Shares change (QoQ)	132.62%
Shares change (YoY)	213.01%
Shares held by insiders	17.15%
Shares held by institutions	35.72%
Shares outstanding	13.7M
Short % of shares	7.56%
Short ratio	3.5 days

Deeper analysis on KZIA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this KZIA report

Is a complete KZIA research report available?

No complete published report is available for Kazia Therapeutics Limited (KZIA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Kazia Therapeutics Limited (KZIA)

Price

Financial snapshot

Fair-value bridge

Latest news · KZIA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All KZIA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on KZIA

Frequently asked questions